EUVIMEDEUVIMED entdecken
Crossref

Treatment Strategies for Recurrent Olfactory Neuroblastoma

Jason R. Crossley, Garret Choby, Eric W. Wang, Georgios A. Zenonos, Paul A. Gardner, Carl H. Snyderman

Journal of Neurological Surgery Part B: Skull Base · 03.08.2026

DOI: 10.1055/a-2919-5250 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neurological Surgery Part B: Skull Base, erschienen am 03.08.2026. Verfasst von Jason R. Crossley und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to describe how olfactory neuroblastoma (ONB) recurrences are managed and whether these salvage strategies lead to freedom from disease at the location of recurrence.

Design

Retrospective cross-sectional analysis.

Setting

Single academic hospital in the United States.

Participants

Patients with recurrent ONB undergoing salvage treatment from April 2006 to February 2021. Main Outcomes and Measures Persistence or freedom from recurrent disease.

Results

A total of 27 cases were identified. Among these cases, 59 recurrences were observed. The mean time to recurrence was 72 months. The mean duration from time of recurrence management to most recent follow-up was 59 months. A total of 19 cases underwent surgery for local sinonasal or local intracranial disease, 20 cases underwent surgery for regional disease, 2 underwent surgery for distant extracranial disease, and no patients underwent surgery for distant intracranial disease. About 22 recurrences were treated with radiation, 8 recurrences were treated with chemotherapy or immunotherapy, and 9 recurrences were treated with radioligand therapy. About 5 patients (20%) had 1-year disease-free survival following salvage treatment and 4 patients (16%) had 5-year disease-free survival following salvage treatment.

Conclusions

Surgery, radiation, and radioligand therapy were the most common salvage treatments used for recurrent OBN. Local sinonasal, local intracranial, and regional recurrences were primarily managed surgically, whereas distal intracranial and distant disease were most often treated with radiation or radioligand therapy. This report is the first to characterize treatment strategies and outcomes used for specific locations of recurrences. Key Points Question: How are olfactory neuroblastoma recurrences managed?

Findings

In this cross-sectional analysis of 27 cases, a novel classification separating intracranial recurrences into local dural or distal dural recurrences was associated with primarily surgical versus non-surgical treatment strategies, respectively, and freedom from or persistence of recurrent disease. Recurrences in the temporalis muscle were associated with an open approach, and Hyams grade was not reported in recurrent cases. Meaning: Classifying intracranial recurrence as local or distal dural may help predict treatment options and measure efficacy. Avoiding surgical seeding during open approaches and validation of Hyams grade in the recurrent setting is warranted.

Zitieren

APA

Crossley, J. R., Choby, G., Wang, E. W., Zenonos, G. A., Gardner, P. A., & Snyderman, C. H. (2026). Treatment Strategies for Recurrent Olfactory Neuroblastoma. Journal of Neurological Surgery Part B: Skull Base. https://doi.org/10.1055/a-2919-5250

Vancouver

Crossley JR, Choby G, Wang EW, Zenonos GA, Gardner PA, Snyderman CH. Treatment Strategies for Recurrent Olfactory Neuroblastoma. Journal of Neurological Surgery Part B: Skull Base. 2026. doi:10.1055/a-2919-5250

BibTeX
@article{Crossley2026,
  author = {Crossley, Jason R. and Choby, Garret and Wang, Eric W. and Zenonos, Georgios A. and Gardner, Paul A. and Snyderman, Carl H.},
  title = {Treatment Strategies for Recurrent Olfactory Neuroblastoma},
  journal = {Journal of Neurological Surgery Part B: Skull Base},
  year = {2026},
  doi = {10.1055/a-2919-5250}
}
Kostenlos starten →